The art of transforming peptides into drug leads is still a dynamic and fertile field in medicinal
chemistry and drug discovery. Peptidomimetics can respond to peptide limitations by …

A large proportion of protein–protein interactions (PPIs) occur between a short peptide and a
globular protein domain; the peptides involved in surface interactions play important roles …

Peptides are a growing therapeutic class due to their unique spatial characteristics that can
target traditionally “undruggable” protein–protein interactions and surfaces. Despite their …

The severe infection is becoming a significant health problem which threaten the lives of
patients and the safety and economy of society. In the way of finding new strategy …

Protein–protein interactions (PPIs) are involved at all levels of cellular organization, thus
making the development of PPI inhibitors extremely valuable. The identification of selective …

The ability to efficiently access cytosolic proteins is desired in both biological research and
medicine. However, targeting intracellular proteins is often challenging, because to reach …

The suite of currently used drugs can be divided into two categories–traditional 'small
molecule'drugs with typical molecular weights of< 500 Da but with oral bioavailability, and …

Our ever‐increasing understanding of biological systems is providing a range of exciting
novel biological targets, whose modulation may enable novel therapeutic options for many …

Protein structure underlies essential biological processes and provides a blueprint for
molecular mimicry that drives drug discovery. Although small molecules represent the lion's …

Stapled α− helical peptides have emerged as a promising new modality for a wide range of
therapeutic targets. Here, we report a potent and selective dual inhibitor of MDM2 and …